Technical Analysis for RDHL - Redhill Biopharma Ltd.

Grade Last Price % Change Price Change
grade B 8.81 0.69% 0.06
RDHL closed up 0.69 percent on Tuesday, March 19, 2019, on 37 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical RDHL trend table...

Date Alert Name Type % Chg
Mar 19 Golden Cross Bullish 0.00%
Mar 19 New Uptrend Bullish 0.00%
Mar 19 Calm After Storm Range Contraction 0.00%
Mar 19 NR7 Range Contraction 0.00%
Mar 19 NR7-2 Range Contraction 0.00%
Mar 19 Up 3 Days in a Row Strength 0.00%
Mar 18 Calm After Storm Range Contraction 0.69%
Mar 18 NR7 Range Contraction 0.69%
Mar 15 180 Bullish Setup Bullish Swing Setup 3.04%
Mar 15 Inside Day Range Contraction 3.04%

Older signals for RDHL ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
RedHill Biopharma Ltd., a biopharmaceutical company, engages in the acquisition and development of patent-protected new formulations and combinations of existing drugs in advanced stages of development. The company's pipeline includes six clinical stage therapeutic candidates comprising RHB-101, a once daily controlled release patented formulation of Carvedilol for the treatment of hypertension, heart failure, and left ventricular dysfunction; RHB-102, a once daily controlled release oral formulation of Ondansetron for the prevention of nausea and vomiting for oncology-support treatments; and RHB-103, a proprietary oral fast dissolving thin film formulation of rizatriptan for the treatment of acute migraine headaches. Its pipeline also consists of RHB-104, a patented antibiotics drug for the treatment of inflammatory bowel disease focused on Crohn's disease patients; RHB-105, an antibiotics and proton pump inhibitor proprietary drug targeting helicobacter pylori infection; and RHB-106, a patented formulation in tablet form for the preparation and cleansing of the gastrointestinal tract. RedHill Biopharma Ltd. was founded in 2009 and is based in Tel Aviv, Israel.
Medicine Biopharmaceutical Autoimmune Diseases Antibiotics Inflammatory Bowel Disease Hypertension Heart Failure Gastroenterology Abdominal Pain Bacteria Nausea Vomiting Crohn's Disease Treatment Of Inflammatory Bowel Disease Treatment Of Hypertension Ventricular Dysfunction
Is RDHL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 11.49
52 Week Low 4.4
Average Volume 86,693
200-Day Moving Average 7.8554
50-Day Moving Average 7.8922
20-Day Moving Average 8.015
10-Day Moving Average 8.31
Average True Range 0.4148
ADX 25.4
+DI 30.1626
-DI 15.6352
Chandelier Exit (Long, 3 ATRs ) 7.955599999999999
Chandelier Exit (Short, 3 ATRs ) 8.4944
Upper Bollinger Band 8.9919
Lower Bollinger Band 7.0381
Percent B (%b) 0.91
BandWidth 24.376794
MACD Line 0.2139
MACD Signal Line 0.1203
MACD Histogram 0.0936
Fundamentals Value
Market Cap 151.2 Million
Num Shares 17.2 Million
EPS -2.46
Price-to-Earnings (P/E) Ratio -3.58
Price-to-Sales 264.36
Price-to-Book 3.16
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.31
Resistance 3 (R3) 9.28 9.10 9.22
Resistance 2 (R2) 9.10 8.97 9.11 9.19
Resistance 1 (R1) 8.95 8.89 9.03 8.98 9.17
Pivot Point 8.77 8.77 8.80 8.78 8.77
Support 1 (S1) 8.62 8.64 8.70 8.65 8.45
Support 2 (S2) 8.44 8.56 8.45 8.43
Support 3 (S3) 8.29 8.44 8.40
Support 4 (S4) 8.32